At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 126 enrolled
Drug / intervention
Dexamethasone +1 moredrug
Likely dose
Dexamethasone 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China
In Brief
A Phase 3 clinical trial evaluating Dexamethasone and Carfilzomib for Relapsed and Refractory Multiple Myeloma. Completed, enrolled 126 participants across 17 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed and Refractory Multiple Myeloma
CountriesChina
CollaboratorsOnyx Therapeutics, Inc.
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartMar 2017
Primary CompletionNov 2018
Study CompletionJun 2021
TodayJul 2026
First PostedJan 24, 2017
Enrollment StartMar 31, 2017
Primary CompletionNov 5, 2018
Study CompletionJun 4, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.4 years ago
Interventions
Dexamethasonedrug
20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles.
Carfilzomibdrug
Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle.